Elevation Oncology, Inc. - Common stock (ELEV)
0.2780
-0.1998 (-41.82%)
Elevation Oncology Inc is a biopharmaceutical company focused on developing targeted therapies for patients with genomically defined cancers
The company is dedicated to understanding the unique genetic drivers of these diseases and aims to create innovative treatment options that address unmet medical needs. By leveraging its expertise in precision medicine and oncology, Elevation Oncology works to advance its clinical pipeline, providing hope to patients with rare and challenging cancer types through personalized and effective therapeutic strategies.
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via Chartmill · March 20, 2025
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · March 20, 2025
Via Benzinga · March 20, 2025
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via Chartmill · March 20, 2025
Via Benzinga · March 20, 2025
Elevation Oncology ends EO-3021 development after Phase 1 results, shifts focus to EO-1022, and plans a major workforce reduction to extend funding.
Via Benzinga · March 20, 2025
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · March 20, 2025
Via Benzinga · March 20, 2025
Via Benzinga · March 13, 2025

Elevation Oncology's ADCs target CLDN18.2 and HER3, with EO-3021 showing promising Phase 1 results and a $6.6 billion TAM in gastric and pancreatic cancers.
Via Benzinga · January 3, 2025

Via Benzinga · January 3, 2025

Via Benzinga · September 27, 2024

Via Benzinga · August 6, 2024

Elevation Oncology shares dropped after initial data from the Phase 1 trial of EO-3021 showed a 42.8% objective response rate in patients with advanced solid tumors expressing Claudin 18.2. No Grade 4 or 5 adverse events were reported. The company plans further trial expansion in 2025.
Via Benzinga · August 6, 2024

GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins.
Via Benzinga · July 18, 2024

By diversifying your portfolio with top stocks for under $10, you can profit from companies that are just starting their growth stories.
Via InvestorPlace · May 27, 2024

Via Benzinga · May 13, 2024

ELEV stock results show that Elevation Oncology missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 2, 2024

Stocks under $7 have greater potential for substantial gains because they start off with lower valuations. Here are some of the best now.
Via InvestorPlace · April 11, 2024

Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.
Via InvestorPlace · April 2, 2024

ELEV stock results show that Elevation Oncology beat analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · March 6, 2024